Mortality from breast cancer is declining in most countries thanks to effective screening programs, early diagnosis, molecular characterization of the different subtypes and biology-driven treatments. A multidisciplinary management of breast cancer patients is therefore the key to success and a breast multidisciplinary team should include – besides the “classic” clinical specialties – pathologists, molecular biologists and geneticists. Furthermore, the availability of multiple diagnostic and therapeutic choices, the increasing costs of new technologies and drugs and the issue of sustainability represent a new challenge for sociallyresponsible clinicians. With this goal in mind, the Programme includes lectureson molecular characterization, updated treatments of early and advanced disease, management of difficult cases and hereditary syndromes and issues of sustainability and drug access across countries.
Clinical case discussions and debates are planned to allow a continuous and fruitful exchange of experiences and opinions between speakers and participants. In order to reward scientific excellence and to foster international cooperation, the International Scientific Committee of the 16th AIBCC will award the 10th International Prize for Breast Cancer Research to a scientist who has published a breakthrough paper in the previous year. We also welcome the presentation of posters from participants and the best poster will be awarded during the Award Ceremony.
The Digital Event is addressed to medical oncologists, pathologists, breast surgeons, radiation oncologists and basic scientists who will have the opportunity to interact with breast cancer leaders and exchange experiences in a friendly atmosphere.

VIRTUAL SESSION I: EVOLUTION IN CANCER PREVENTION AND DIAGNOSIS
1. Beyond BRCA1/2: Management of women with other predisposition gene mutations - Claudine Isaacs
2. Tumor infiltrating lymphocytes in breast cancer: role in clinical practice Maria Vittoria Dieci
3. Clinical impact of genomics for HER2+ and TNBC - Aleix Prat
4. New biomarkers ready for prime time (PDL1, PI3K, BRCA, AR etc) Giuseppe Viale

VIRTUAL SESSION II: LOCOREGIONAL TREATMENT, LIFE AFTER BC
1. Is it safe to avoid axillary node dissection in SN+ patients? Elefterios Mamounas
2. PMRT after immediate breast reconstruction: the way forward Philip Poortmans
3. Hormone replacement therapy after BC treatment - Fedro Peccatori
4. Bone Health - Ingo Diel
5. Follow up: how, who, why - Jacek Jassem

VIRTUAL SESSION III: SYSTEMIC TREATMENT FOR EBC
1. How to identify HR+ who are likely to benefit from adjuvant chemotherapy - Carlo Tondini
2. Risk adapted endocrine therapy for HR+ BC (from 5 y tamoxifen to 10 years or more AI) - Sibylle Loibl
3. Neoadjuvant therapy for HER2+ disease: new data, new standard? Valentina Guarneri
4. Is immunotherapy ready for prime time for early TNBC? - Hope Rugo
5. Post-Neoadjuvant treatments: achievements and opportunities - Pier Franco Conte
6. CDK4/6 inhibitors for early breast cancer - Gabriel N. Hortobagyi

VIRTUAL SESSION IV: ADVANCED BREAST CANCER
1. Biomarker driven treatment sequencing for HR+ ABC: attempt to reconcile science and label indications - Stephen Johnston
2. HER2+ disease: integrating the drug tsunami - Sandra Swain
3. TNBC: challenges and opportunities - Miguel Martin
4. New promising drugs for advanced breast cancer - Giuseppe Curigliano

VIRTUAL SESSION V: AFFORDABILITY OF BREAST CANCER COSTS AND EQUITY IN ACCESS
1. The US system: lights and shadows - Thomas Buchholz
2. Reimbursement process in Italy - Francesco Perrone
3. Real World Evidence in Oncology: Opportunities and Pitfalls - Paolo Bruzzi
4. The wave of biosimilars - Hope Rugo
5. The EBCC 2020 Manifesto: how to translate this to clinical reality Philip Poortmans

Per partecipare all’evento è necessario completare la procedura online di iscrizione.
L’iscrizione a questo corso è gratuita.

Questionario a risposta multipla e a doppia randomizzazione. Si effettua online con l'obbligo di rispondere correttamente ad almeno il 75 percento delle domande per il suo superamento. È prevista la possibilità di ripetizione in caso di esito negativo

Contenuti tecnico-professionali (conoscenze e competenze) specifici di ciascuna professione, di ciascuna specializzazione e di ciascuna attività ultraspecialistica, ivi incluse le malattie rare e la medicina di genere